Alanine Transaminase

ALT (also called alanine aminotransferase) is an enzyme — a protein that helps chemical reactions happen — found mainly inside liver cells, with smaller amounts in kidneys and skeletal muscle. When your liver cells are healthy, ALT stays inside those cells. If liver cells become inflamed, injured, or stressed, ALT can leak into the bloodstream, where it’s easily measured with a routine blood test. That’s why ALT is often included in a liver panel or comprehensive metabolic panel, usually alongside AST (aspartate transaminase), alkaline phosphatase, and bilirubin.

ALT is considered more liver-specific than AST because ALT is present in much higher concentrations in the liver than in most other tissues — so it’s particularly useful for identifying liver-related stress. “Normal” ALT ranges vary by sex and by laboratory, but many traditional reference ranges are roughly 29–33 IU/L for men and 19–25 IU/L for women, with more recent standardised data suggesting upper limits closer to ~42 IU/L for men and ~30 IU/L for women. Importantly, “normal” isn’t one-size-fits-all: ALT can be influenced by age, body weight, and metabolic health. For example, people with higher body weight or conditions like type 2 diabetes can show mildly higher ALT even without obvious liver disease. That’s why ALT is best interpreted in context — alongside symptoms, history, and related biomarkers — rather than as a standalone number.

ALT matters because it gives a direct signal about liver cell health and also acts as a practical “metabolic barometer” for how your body is handling energy, inflammation, and detoxification demands. Your liver performs hundreds of essential functions: it processes nutrients from food, helps regulate blood sugar, produces proteins needed for blood clotting, stores vitamins and minerals, and helps filter and transform substances the body wants to clear. When liver cells are injured, ALT often rises before symptoms appear — so it can be an early opportunity to detect and address problems while they’re still reversible.

Mildly elevated ALT (often defined as less than five times the upper limit of normal) is common, affecting roughly 10–20% of the general population, and can signal underlying conditions that may progress if left unaddressed. The most common cause is metabolic dysfunction–associated steatotic liver disease (MASLD) (previously called NAFLD), where excess fat accumulates in liver cells. MASLD is closely linked to insulin resistance, type 2 diabetes, central weight gain (waist circumference), and the broader metabolic syndrome. Over time, fatty liver can progress from simple fat accumulation to inflammation (often referred to as MASH, previously NASH), and potentially to fibrosis (scarring). Advanced fibrosis can eventually lead to cirrhosis and increases risk for liver failure and liver cancer. This is why ALT is not just “a liver number” — it can be an early sign of metabolic strain.

ALT is also tied to overall health outcomes beyond the liver. Population studies show ALT tends to rise with increasing BMI, larger waist circumference, physical inactivity, and alcohol intake. Elevated ALT has also been associated with increased risk of broader cardiometabolic issues. At the other end of the spectrum, extremely low ALT in older adults has been linked to frailty, sarcopenia (muscle loss), disability, and higher mortality risk — suggesting ALT can reflect broader physiological reserve and nutrition/muscle status in some contexts. Finally, ALT can be influenced by factors outside the liver, including strenuous exercise, certain medications, thyroid disorders, celiac disease, and muscle injury/breakdown (rhabdomyolysis).

Dietary factors

Diet strongly influences ALT, mostly through effects on liver fat and insulin sensitivity. Excess calories — especially from refined carbohydrates, added sugars, saturated fats, and sugar-sweetened beverages — can increase liver fat and inflammation, raising ALT. Fructose in particular (including high-fructose sweetened drinks) has been shown to worsen liver fat accumulation and can contribute to inflammation and fibrosis progression even without major weight change. In contrast, dietary patterns such as a Mediterranean-style diet (vegetables, fruits, whole grains, legumes, olive oil, nuts/seeds, and fish; minimal processed foods and red meat) can reduce liver fat and improve insulin sensitivity, sometimes even without weight loss. Coffee (regular or decaf) is consistently associated with lower ALT and lower liver disease risk, with benefits most pronounced around 3+ cups per day in observational research. Diets rich in antioxidants — especially foods high in carotenoids (carrots, sweet potatoes, leafy greens, tomatoes) and vitamin C — are inversely associated with abnormal ALT, suggesting protective effects against liver injury.

Lifestyle factors

Regular exercise reduces liver fat and ALT even without dramatic weight loss. Both aerobic activity (brisk walking, jogging, cycling, swimming) and resistance training (weights) help, and combined approaches often look most effective. Weight loss is one of the strongest interventions for improving ALT in fatty liver disease: around 3–5% weight loss can reduce liver fat and ALT, while 7–10%+ can improve liver inflammation and may help reverse fibrosis. Weight gain tends to worsen ALT and progression risk. Alcohol increases ALT and liver injury risk, even at moderate intake. Smoking is linked to higher ALT and worse liver health. Sleep, stress, and meal timing may also influence liver markers; some evidence suggests time-restricted eating (e.g., eating within an 8–12 hour daytime window) may support liver health.

Micronutrients and related biomarkers

ALT can be influenced by micronutrient status and oxidative stress. Higher iron levels and transferrin saturation have been linked with elevated ALT, while lower blood levels of carotenoids and vitamin C are associated with higher risk of abnormal ALT. In people with fatty liver disease/MASH, vitamin E at 400–800 IU daily has been shown to reduce ALT and AST in clinical studies. L-carnitine (typically 500–4000 mg daily) may reduce ALT, with stronger effects reported at higher doses and longer use in liver disease contexts. Selenium levels have shown positive correlations with ALT in some studies, though clinical significance is less clear. ALT should also be interpreted alongside AST, and in the broader context of metabolic markers that often travel with fatty liver (e.g., insulin resistance features).

Medications, supplements, and environmental influences

ALT can rise due to drug-induced liver injury. Common contributors include some antibiotics (notably amoxicillin-clavulanate), anti-epileptic drugs, anti-tuberculosis drugs, and paracetamol (in overdose or long term high use). Statins can raise liver enzymes in some people, though true liver injury is rare. Importantly, herbal and dietary supplements can also raise ALT — examples include green tea extract, bodybuilding supplements, some weight loss products, and herbs such as kava. Environmental toxins, viral infections (hepatitis A/B/C/E, EBV, CMV), sepsis, and intense physical exertion or muscle injury can also elevate ALT. Because these causes can overlap, it’s essential that a clinician knows everything you take (prescriptions, over-the-counter products, and supplements) when interpreting ALT.

If your results are high

Diet:

• Shift toward a Mediterranean-style pattern: vegetables at most meals; legumes several times per week; whole grains; olive oil; nuts/seeds; and fish regularly, while limiting refined carbs, added sugars, and sugar-sweetened drinks.

• Specifically reduce fructose-heavy sweetened beverages.

• Include antioxidant-rich foods daily (carotenoid-rich vegetables like carrots, sweet potato, leafy greens, tomatoes; and vitamin C-rich produce).

Lifestyle: Build a weekly routine that includes both aerobic and resistance exercise. If weight loss is relevant, target sustainable changes — about 3–5% weight loss can reduce liver fat and ALT, and 7–10%+ can improve inflammation and potentially fibrosis. Avoid alcohol (as it increases ALT and liver injury risk) and avoid smoking (linked to higher ALT). Consider time-restricted eating within an 8–12 hour daytime window if suitable.

Supplements: In fatty liver/MASH contexts, vitamin E 400–800 IU/day has been shown to reduce ALT/AST; L-carnitine 500–4000 mg/day may also reduce ALT (benefits more consistent at higher doses and longer use). Discussing these with a medical professional is recommended.

Additional tests to consider: Review AST and the broader liver panel; evaluate metabolic risk factors (linked to MASLD); and consider assessment of iron status (as higher iron measures have been associated with elevated ALT). Also review all medications and supplements for liver effects.

If your results are low

Diet: Maintain adequate overall nutrition, including regular protein and micronutrient-rich foods, because very low ALT — particularly in older adults — has been linked to frailty and low physiological reserve.

Lifestyle: If you are older or have concerns about muscle mass, discuss whether low ALT may reflect sarcopenia/frailty risk and whether strength training and nutrition support are appropriate in your case.

Supplements: No specific supplement advice is appropriate from ALT alone; focus on nutrition and context, and discuss with a medical professional if low ALT is unexpected or accompanied by weakness or unintentional weight loss.

Additional tests to consider: Review ALT in the context of overall liver panel and general health status; in older adults, clinicians may interpret low ALT alongside functional status and muscle/nutrition markers.

1. Arif-Tiwari, H., Porter, K. K., et al. (2023). ACR Appropriateness Criteria® abnormal liver function tests. Journal of the American College of Radiology, 20(11S), S302–S314. https://doi.org/10.1016/j.jacr.2023.08.023

2. Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG clinical guideline: Evaluation of abnormal liver chemistries. The American Journal of Gastroenterology, 112(1), 18–35. https://doi.org/10.1038/ajg.2016.517

3. Langan, R. C., & Hines-Smith, K. A. (2024). Mildly elevated liver transaminase levels: Causes and evaluation. American Family Physician, 110(6), 585–591.

4. Pratt, D. S., & Kaplan, M. M. (2000). Evaluation of abnormal liver-enzyme results in asymptomatic patients. The New England Journal of Medicine, 342(17), 1266–1271. https://doi.org/10.1056/NEJM200004273421707

5. Valenti, L., Pelusi, S., Bianco, C., et al. (2021). Definition of healthy ranges for alanine aminotransferase levels: A 2021 update. Hepatology Communications, 5(11), 1824–1832. https://doi.org/10.1002/hep4.1794

6. Tan, E. X., Huang, D. Q., Yee, N. T. S., et al. (2024). Upper limit of normal ALT levels in health and metabolic diseases: Pooled analysis of 423,355 individuals with bootstrap modelling. Alimentary Pharmacology & Therapeutics, 59(8), 984–992. https://doi.org/10.1111/apt.17914

7. Duell, P. B., Welty, F. K., Miller, M., et al. (2022). Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 42(6), e168–e185. https://doi.org/10.1161/ATV.0000000000000153

8. Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., et al. (2023). AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), 1797–1835. https://doi.org/10.1097/HEP.0000000000000323

9. Younossi, Z. M., Corey, K. E., & Lim, J. K. (2021). AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in NAFLD: Expert review. Gastroenterology, 160(3), 912–918. https://doi.org/10.1053/j.gastro.2020.11.051

10. Ding, J., & Zhang, Y. (2021). Associations of coffee consumption with circulating ALT and AST: A meta-analysis of observational studies. Journal of the American College of Nutrition, 40(3), 261–272. https://doi.org/10.1080/07315724.2020.1755912

11. Xiao, Q., Sinha, R., Graubard, B. I., & Freedman, N. D. (2014). Inverse associations of total and decaffeinated coffee with liver enzyme levels in NHANES 1999–2010. Hepatology, 60(6), 2091–2098. https://doi.org/10.1002/hep.27367

12. Ruhl, C. E., & Everhart, J. E. (2005). Coffee and caffeine consumption reduce the risk of elevated serum ALT activity in the United States. Gastroenterology, 128(1), 24–32. https://doi.org/10.1053/j.gastro.2004.09.075

13. Ruhl, C. E., & Everhart, J. E. (2003). Relation of elevated serum ALT activity with iron and antioxidant levels in the United States. Gastroenterology, 124(7), 1821–1829. https://doi.org/10.1016/S0016-5085(03)00395-0

14. Hoofnagle, J. H., & Björnsson, E. S. (2019). Drug-induced liver injury—Types and phenotypes. The New England Journal of Medicine, 381(3), 264–273. https://doi.org/10.1056/NEJMra1816149

15. Hoofnagle, J. H., Van Natta, M. L., Kleiner, D. E., et al. (2013). Vitamin E and changes in serum ALT levels in patients with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics, 38(2), 134–143. https://doi.org/10.1111/apt.12352

16. Pirmadah, F., Ramezani-Jolfaie, N., Mohammadi, M., et al. (2020). Does L-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled trials. European Journal of Nutrition, 59(5), 1767–1783. https://doi.org/10.1007/s00394-019-02068-4